(25 days)
Not Found
No
The description focuses on the mechanical design and function of a catheter system for delivering agents, with no mention of data processing, algorithms, or learning capabilities.
No
The device delivers therapeutic agents but is not a therapeutic device itself; it is a microcatheter designed to facilitate the delivery of those agents.
No
Explanation: The device is intended for delivering radiopaque media and therapeutic agents during angiographic procedures, and its description focuses on its function as a conduit for various agents. It does not state that it is used to diagnose a medical condition.
No
The device description clearly outlines a physical medical device, a microcatheter with an expandable tip, and details its physical components, materials, and mechanical properties. There is no mention of software as the primary or sole component.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is for delivering radiopaque media and therapeutic agents to selected sites in the peripheral vascular system during angiographic procedures. This is an in vivo (within a living organism) application, not an in vitro (outside of a living organism) diagnostic test performed on samples like blood or tissue.
- Device Description: The description details a microcatheter designed for insertion into blood vessels to deliver substances. This is a medical device used directly on a patient, not a reagent or instrument used to analyze biological samples.
- Lack of IVD Characteristics: There is no mention of analyzing biological samples, detecting analytes, or providing diagnostic information based on laboratory testing.
The device is clearly intended for therapeutic and imaging delivery within the body, which falls under the category of a medical device, not an in vitro diagnostic device.
N/A
Intended Use / Indications for Use
The Surefire Infusion System 021 is intended for use in angiographic procedures.
It delivers radiopaque media and therapeutic agents to selected sites in the peripheral vascular system.
Product codes (comma separated list FDA assigned to the subject device)
DQO
Device Description
The Surefire Infusion System 021 is a 0.021" lumen coaxial microcatheter with the Surefire Expandable Tip at the distal end. It has an outer sheath to facilitate expanding and collapsing the Surefire Expandable Tip. The Surefire 021, serves as the conduit for physician-specified agents such as contrast agents, flush solutions, and embolic beads. It is compatible with standard 0.018" guide wires, infusion syringes, rotating hemostatic valves (RHVs/Tuohy Borsts), and embolic hydrogel particles 500um or less in size and glass microspheres 110um or less in size. The Surefire 021 has a Teflon inner liner to provide a lubricious surface for passage of physician-specified agents and other accessory devices. The device is hydrophilically coated. The soft, pliable, funnel-shaped Surefire Expandable Tip is sized for use in vessels of 1.5mm to 4 mm.
There are two radiopaque markers located just proximal and distal to the Surefire Expandable Tip. The Tip can be expanded or collapsed up to 3 times for re-positioning an interventional procedure by simply retracting or advancing the inner microcatheter while holding the outer sheath stationary. When expanded, the Expandable Tip is designed to improve infusion efficiency of compatible embolic agents while maintaining antegrade flow in various size vessels.
The Surefire Infusion System 021 is provided sterile (EtO) for single patient use.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
peripheral vascular system
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Design verification testing was performed which demonstrated that the Surefire Infusion System 021 meets its specified performance requirements, and is equivalent to the performance of the predicate device. Testing included visual and dimensional inspection, and tests for hydrophilic coating lubricity and wear, particulates, high pressure injection (burst pressure), tensile strength, kink resistance, torque resistance, trackability, infusion agent compatibility, embolic agent compatibility, antegrade flow and infusion efficiency. The results of testing demonstrated that the Surefire Infusion System 021 meets its specifications and is comparable in mechanical strength and performance to the predicate Surefire Infusion System.
An animal study was performed to assess the comparative acute performance of the Surefire Infusion System 021to the predicate device, as defined by physician's in a simulated clinical environment. The Surefire Infusion System 021was found to have acceptable performance. Additionally, the Surefire Infusion System 021was found to have comparable performance to the predicate device.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 870.1200 Diagnostic intravascular catheter.
(a)
Identification. An intravascular diagnostic catheter is a device used to record intracardiac pressures, to sample blood, and to introduce substances into the heart and vessels. Included in this generic device are right-heart catheters, left-heart catheters, and angiographic catheters, among others.(b)
Classification. Class II (performance standards).
0
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized caduceus symbol, which is a staff with two snakes entwined around it. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular pattern around the caduceus.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
June 11, 2015
Surefire Medical, Inc. c/o Mark Job Regulatory Technical Services LLC 1394 25th Street NW Buffalo, MN 55313
Re: K143588
Trade/Device Name: Surefire Infusion System 021 Regulation Number: 21 CFR 870.1200 Regulation Name: Diagnostic intravascular catheter Regulatory Class: Class II Product Code: DQO Dated: December 17, 2014 Received: December 18, 2014
Dear Mr. Job:
This letter corrects our substantially equivalent letter of January 12, 2015.
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading,
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must
1
Page 2 - Mr. Mark Job
comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
for
Sincerely yours,
Kenneth J. Cavanaugh -S
Bram D. Zuckerman, M.D. Director
Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known)
Device Name Surefire Infusion System 021
Indications for Use (Describe)
The Surefire Infusion System 021 is intended for use in angiographic procedures.
It delivers radiopaque media and therapeutic agents to selected sites in the peripheral vascular system.
Type of Use (Select one or both, as applicable)
| ☑ Prescription Use (Part 21 CFR 801 Subpart D) | ☐ Over-The-Counter Use (21 CFR 801 Subpart C) |
|---|---|
| -------------------------------------------------------------------------------- | ---------------------------------------------------------------------------------------- |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
510(K) SUMMARY
Device Name
Surefire Infusion System 021
Manufacturer Name and Address
Surefire Medical, Inc. 6272 W. 91st Avenue Westminster, CO 80031 Owner Operator Number: 10038066
Submitter Contact Information
Surefire Medical, Inc. 6272 W. 91st Avenue Westminster, CO 80031 Lynne Aronson. VP Regulatory Affairs and Quality Assurance Contact: Contact: Phone: Phone: 303-426-1222 Fax: 303-426-1223
Common, Classification & Proprietary Names
| Common Name: | diagnostic intravascular catheter |
|---|---|
| Classification Name: | diagnostic intravascular catheter |
| Proprietary Name: | Surefire Infusion System 021 |
| Classification: | Class II |
| Classification Panel: | Cardiovascular Devices |
| Classification Regulation: | 21 CFR 870.1200 |
| Product Code: | DQO |
Predicate Device
Surefire Infusion System 트
Device Description
The Surefire Infusion System 021 is a 0.021" lumen coaxial microcatheter with the Surefire Expandable Tip at the distal end. It has an outer sheath to facilitate expanding and collapsing the Surefire Expandable Tip. The Surefire 021, serves as the conduit for physician-specified agents such as contrast agents, flush solutions, and embolic beads. It is compatible with standard 0.018" guide wires, infusion syringes, rotating hemostatic valves (RHVs/Tuohy Borsts), and embolic hydrogel particles 500um or less in size and glass microspheres 110um or less in size. The Surefire 021 has a Teflon inner liner to provide a lubricious surface for passage of physician-specified agents and other accessory devices. The device is hydrophilically coated. The soft, pliable, funnel-shaped Surefire Expandable Tip is sized for use in vessels of 1.5mm to 4 mm.
There are two radiopaque markers located just proximal and distal to the Surefire Expandable Tip. The Tip can be expanded or collapsed up to 3 times for re-positioning an interventional procedure by simply retracting or advancing the inner microcatheter while holding the outer sheath stationary. When expanded, the Expandable Tip is designed to improve infusion efficiency of compatible embolic agents while maintaining antegrade flow in various size vessels.
The Surefire Infusion System 021 is provided sterile (EtO) for single patient use.
4
Indications for Use
The Surefire Infusion System 021 is intended for use in angiographic procedures. It delivers radiopaque media and therapeutic agents to selected sites in the peripheral vascular system.
Biocompatability Testing
Biocompatibility testing of the patient-contact materials used in the construction of the catheter was performed in accordance with ISO 10993-1 for an external communicating device in contact with circulating blood with a limited duration of less than 24 hours. The following testing was conducted in accordance with GLP by NAMSA (Northwood, OH).
The following biocompatibility testing was conducted on the Surefire Infusion System (K121677) which are constructed of the same materials as the Surefire Infusion System 021. Therefore, the biocompatibility test requirements for the Surefire Infusion System (21 were met by leveraging previously completed biocompatibility testing.
| Category | Standard | Test Method |
|---|---|---|
| Cytotoxicity | ISO 10993-5 | Cytotoxicity Study Using the ISO Elution Method - 1x Minimal |
| Essential Media Extract | ||
| Sensitization | ISO 10993-10 | ISO Maximization Sensitization Study - Extract - 0.9% Sodium |
| Chloride Solution Extract | ||
| ISO Maximization Sensitization Study - Extract – Sesame Oil, NF | ||
| Extract | ||
| Irritation or | ||
| Intracutaneous | ||
| Reactivity | ISO 10993-10 | ISO Intracutaneous Study - Extract - 0.9% Sodium Chloride Solution |
| Extract | ||
| ISO Intracutaneous Study - Extract - Sesame Oil, NF Extract | ||
| Systemic Toxicity | ISO 10993-11 | ISO Systemic Toxicity Study - Extract - 0.9% Sodium Chloride |
| Solution Extract | ||
| ISO Systemic Toxicity Study - Extract - Sesame Oil, NF Extract | ||
| Pyrogen – Material Mediated – 0.9% Sodium Chloride Solution | ||
| Extract | ||
| Hemocompatability | ISO 10993-4 | ASTM Hemolysis – CMF-PBS Extract |
| C3a Complement Assay - Normal Human Serum Extract | ||
| SC5b-9 Complement Assay - Normal Human Serum Extract | ||
| Coagulation - ASTM Partial Thromboplastin Time |
Additionally, testing for thrombogenicity was performed on the Surefire Infusion System 021 Catheter as a part of an Animal Study.
The results of all of the biocompatibility testing did not indicate any significant biological reaction that would affect the patient due to contact with the materials used in the device construction.
5
Performance Testing
Design verification testing was performed which demonstrated that the Surefire Infusion System 021 meets its specified performance requirements, and is equivalent to the performance of the predicate device. Testing included visual and dimensional inspection, and tests for hydrophilic coating lubricity and wear, particulates, high pressure injection (burst pressure), tensile strength, kink resistance, torque resistance, trackability, infusion agent compatibility, embolic agent compatibility, antegrade flow and infusion efficiency.
The results of testing demonstrated that the Surefire Infusion System 021 meets its specifications and is comparable in mechanical strength and performance to the predicate Surefire Infusion System.
Animal Testing
An animal study was performed to assess the comparative acute performance of the Surefire Infusion System 021to the predicate device, as defined by physician's in a simulated clinical environment. The Surefire Infusion System 021was found to have acceptable performance. Additionally, the Surefire Infusion System 021was found to have comparable performance to the predicate device.
Substantial Equivalence
The Surefire Infusion System 021is substantially equivalent in intended use, design, and technology/principles of operation to the predicate.
Comparative Summary: Design / Technological Characteristics
The Surefire Infusion System 021 and predicate device are coaxial microcatheters with the Surefire Expandable Tip at the distal end. Both infusion systems have an outer catheter to facilitate expanding and collapsing the Surefire Expandable Tip.
The Surefire Infusion System 021 and the predicate device are constructed of similar materials utilizing similar construction and manufacturing processes.
The Surefire Infusion System 021 and predicate device have similar dimensions, with the Surefire Infusion System 021 having smaller outer and inner diameters. Both catheters are 120 cm in length. Due to the smaller inner lumension, the maximum sized embolic beads that are compatible with the Surefire Infusion System 021 are smaller than with the predicate device.
The Surefire Infusion System 021 and predicate device are provided in identical packaging, sterilized by ethylene oxide, and labeled for single use only.
Comparative Summary: Indications for Use
The Surefire Infusion System 021 has the same indications for use as the predicate device. Both devices are intended for use in angiographic procedures to deliver radiopaque media and therapeutic agents to selected sites in the peripheral vascular system.
Comparative Summary: Performance
Animal and bench performance test data demonstrate that the Surefire Infusion System 021 performance is comparable to the predicate device.
In summary, the Surefire Infusion System 021 is substantially equivalent in intended use, design, and technology/principles of operation to the predicate. Animal and bench performance test data demonstrate that the Surefire Infusion System 021 performance is comparable to the predicate device. Differences between the devices do not raise any issues of safety or effectiveness.